A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business. Cara is a biopharmaceutical company that has been focused on leading a new treatment paradigm to improve the lives of patients suffering from chronic pruritus. Cara has developed an IV formulation of difelikefalin, which is approved for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis in the United States, the European Union, or EU, and multiple other countries. The IV formulation is out-licensed worldwide. On June 14, 2024, Cara’s Board of Directors approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value after Cara announced its decision to discontinue the clinical program in notalgia paresthetica, or NP, on June 12, 2024.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | 135M |
| Net Income | -19M | -71M | -119M | -85M | -88M | 8.4M |
| EPS | $-7.69 | $-46.59 | $-78.78 | $-57.24 | $-62.64 | $6.48 |
| Free Cash Flow | 0 | -62M | -94M | -79M | -60M | -5.8M |
| ROIC | -49.8% | -105.2% | -168.1% | -53.8% | -38.9% | 2.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -10.54 | 1.20 | 0.15 | 0.09 | 0.09 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -25M | -58M | -121M | -88M | -89M | 5.4M |
| Operating Margin | 0.0% | - | - | - | - | 4.0% |
| ROE | -66.8% | -270.0% | -207.6% | -53.8% | -38.9% | 3.4% |
| Shares Outstanding | 9M | 2M | 2M | 1M | 1M | 1M |
Tvardi Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Tvardi Therapeutics, Inc. (TVRD) has a 5-year average return on invested capital (ROIC) of -72.7%. This is below average and may indicate limited pricing power.
Tvardi Therapeutics, Inc. (TVRD) has a market capitalization of $30M. It is classified as a small-cap stock.
Tvardi Therapeutics, Inc. (TVRD) does not currently pay a regular dividend.
Tvardi Therapeutics, Inc. (TVRD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Tvardi Therapeutics, Inc. (TVRD) generated $-62 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Tvardi Therapeutics, Inc. (TVRD) reported earnings per share (EPS) of $-46.59 in its most recent fiscal year.
Tvardi Therapeutics, Inc. (TVRD) has a return on equity (ROE) of -270.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for Tvardi Therapeutics, Inc. (TVRD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Tvardi Therapeutics, Inc. (TVRD) has a book value per share of $-3.02, based on its most recent annual SEC filing.